logo

Global Blood Therapeutics (GBT)



Trade GBT now with
  Date
  Headline
6/18/2018 2:06:31 PM Wedbush Reiterates Global Blood Therapeutics (GBT) At Outperform With $70 Price Target
6/15/2018 2:35:07 AM GBT Announces New Phase 2a Voxelotor Data In Adolescents With Sickle Cell Disease
6/7/2018 12:32:55 PM BMTC Group Q1 EPS $0.13 Vs. Breakeven Year Go
5/25/2018 2:34:24 PM Wedbush Reiterates Global Blood Therapeutics (GBT) At Outperform With $70 Price Target
3/14/2018 6:27:29 AM Wedbush Is Lowering Global Blood Therapeutics (GBT) FY18 Estimate To -3.71 From -2.80
3/14/2018 6:27:12 AM Wedbush Is Cutting Global Blood Therapeutics (GBT) Q4 18 Estimate To -0.97 From -0.73
3/14/2018 6:27:01 AM Wedbush Is Cutting Global Blood Therapeutics (GBT) Q3 18 Estimate To -0.94 From -0.71
3/14/2018 6:26:45 AM Wedbush Is Cutting Global Blood Therapeutics (GBT) Q2 18 Estimate To -0.92 From -0.69
3/14/2018 6:26:30 AM Wedbush Is Cutting Global Blood Therapeutics (GBT) Q1 18 Estimate To -0.89 From -0.67
3/14/2018 6:25:48 AM Wedbush Reiterates Global Blood Therapeutics (GBT) At Outperform With $73 Price Target
3/6/2018 8:10:39 AM Global Blood Therapeutics Appoints David Johnson As Chief Commercial Officer
1/23/2018 8:24:12 AM William Blair Starts Global Blood Therapeutics (GBT) At Outperform
1/10/2018 8:52:20 AM Orphan Rare Diseases R&D Advancements Increase Novel Therapeutic Options For Drug Development Pipeline